Diamyd Medical reports on results from its European Phase III study

 

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd® did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed Type 1 diabetes patients.